Thomas Sciascia, Chief Scientific Officer at Trevi Therapeutics, Inc. (TRVI), sold 16,496 shares at $2.96 ($49K) on 2024-08-19, disclosed to the SEC on 2024-08-21.
Open-market sale of $49k TRVI by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| TRVI | SELL | 2024-05-31 | $272K | — | Filing → |